Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company headquartered in Geneva, Switzerland, specializing in the development of novel small molecule allosteric modulators for neurological disorders. These orally available drugs target receptors to offer potential therapeutic advantages over conventional treatments by fine-tuning protein activity. Its lead candidate, dipraglurant (mGlu5 negative allosteric modulator), is under evaluation for post-stroke sensorimotor recovery, Parkinson's disease levodopa-induced dyskinesia, and traumatic brain injury recovery. Collaborations include Janssen Pharmaceuticals advancing ADX71149 (mGlu2 PAM) for schizophrenia and epilepsy, and Indivior developing GABAB PAM for substance use disorders. Addex maintains a robust preclinical pipeline featuring GABAB PAM for chronic cough and pain, mGlu7 NAM for post-traumatic stress and mood disorders, mGlu4 PAM for Parkinson's, mGlu3 PAM for neurodegeneration, and M4 PAM for schizophrenia. With a lean team of two employees, the company holds a 20% stake in Neurosterix LLC, advancing additional allosteric programs, underscoring its innovative role in neuroscience drug discovery.